



## **The p63 target HBP-1 is required for keratinocyte differentiation and stratification.**

Roberto Mantovani, Serena Borrelli, Eleonora Candi, Diletta Dolfini, Olì Maria Victoria Grober, Alessandro Weisz, Gennaro Melino, Alessandra Viganò, Bing Hu, Gian Paolo Dotto

### **► To cite this version:**

Roberto Mantovani, Serena Borrelli, Eleonora Candi, Diletta Dolfini, Olì Maria Victoria Grober, et al.. The p63 target HBP-1 is required for keratinocyte differentiation and stratification.. Cell Death and Differentiation, 2010, 10.1038/cdd.2010.59 . hal-00542927

**HAL Id: hal-00542927**

**<https://hal.science/hal-00542927>**

Submitted on 4 Dec 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Running title: HBP1 in skin differentiation.

**The p63 target HBP-1 is required for skin differentiation and stratification.**

Serena Borrelli<sup>1</sup>, Eleonora Candi<sup>2</sup>, Bing Hu<sup>3</sup>, Diletta Dolfini<sup>1</sup>, Maria Ravo<sup>4</sup>, Olì Maria Victoria Grober<sup>4</sup>, Alessandro Weisz<sup>4,5</sup>, GianPaolo Dotto<sup>3</sup>, Gerry Melino<sup>2,6</sup>, Maria Alessandra Viganò<sup>1</sup> and Roberto Mantovani<sup>1\*</sup>.

1) Dipartimento di Scienze Biomolecolari e Biotecnologie. Università degli Studi di Milano. Via Celoria 26, 20133 Milano, Italy.

2) Biochemistry IDI-IRCCS laboratory, c/o University of Rome "Tor Vergata", Via Montpellier 1, 00133 Roma, Italy.

3) Department of Biochemistry, University of Lausanne, Chemin des Boveresses 155, Epalinges, CH-1066, Switzerland.

4) Dipartimento di Patologia Generale and Centro Grandi Apparecchiature, Seconda Università di Napoli, vico L. De Crecchio 7, 80138 Napoli, Italy.

5) AIRC Naples Oncogenomics Centre, c/o CEINGE Biotecnologie Avanzate, via Comunale Margherita 482, 80145 Napoli, Italy.

6) Medical Research Council, Toxicology Unit, Hodgkin Building, Leicester University, Lancaster Road, P.O. Box 138, Leicester LE1 9HN, UK.

\*Corresponding author. Phone: 39-02-50315005; Fax: 39-02-50315044; E-mail: [mantor@unimi.it](mailto:mantor@unimi.it)

Keywords: HBP1, p63, keratinocytes, differentiation.

Abbreviations: TAp63, amino-terminal Transcriptional Activation domain-containing p63;  $\Delta$ Np63, transcriptional activation domain-deleted p63; CHIP, chromatin immunoprecipitation; HBP1, HMG Binding Protein 1; RNAi, RNA interference; NHEK, Normal Human Epidermal Keratinocytes; KRT, keratin; tg, transgenic mice; KO, knockout mice.

Total characters: 58034

## ABSTRACT

Genetic experiments established that p63 is crucial for the development and maintenance of pluristratified epithelia. In an RNAi screening for targets of p63 in keratinocytes, we identified the transcription factor HBP1. HBP1 is an HMG-containing repressor transiently induced during differentiation of several cell lineages. We investigated the relationship between the two factors: using RNAi, overexpression, ChIPs and transient transfections with reporter constructs, we established that HBP1 is directly repressed by p63. This was further confirmed *in vivo*, by evaluating expression in p63 KO mice and in transgenics expressing p63 in basal keratinocytes. Consistent with these findings, expression of HBP1 increases upon differentiation of primary keratinocytes and HaCaT cells in culture, and it is higher in the upper layers of human skin. Inactivation of HBP1 by RNAi prevents differentiation of keratinocytes and stratification of organotypic skin cultures. Finally, we analyzed the keratinocytes transcriptome after HBP1 RNAi: in addition to repression of growth promoting genes, unexpected activation of differentiation genes was uncovered, coexisting with repression of other genes involved in epithelial cornification. Our data indicate that suppression of HBP1 is part of the growth-promoting strategy of p63 in the lower layers of epidermis and that HBP1 temporally coordinates expression of genes involved in stratification leading to the formation of the skin barrier.

## INTRODUCTION.

p63 is a transcription factor -TF- homologous to p53 and p73. p53 directs the response to DNA-damage by impinging on cell-cycle control and pro-apoptotic pathways (1), while p63 is involved in the development and maintenance of pluri-stratified epithelia (2). Six p63 proteins have been described, resulting from two distinct promoters -TAp63 and  $\Delta$ Np63- and from alternative mRNA splicing - $\alpha$ ,  $\beta$ ,  $\gamma$ - at the 3' end of the gene. TAp63 contain a transcriptional activation -TA- domain which is missing in the N-terminally-deleted  $\Delta$ Np63 isoforms; differential splicing generates isoforms with or without a sterile alpha motif -SAM- domain, allegedly implicated in protein-protein interactions. The relative properties and functions of these isoforms are still not fully understood, but the major isoform present in keratinocytes and other multi-layered epithelia -  $\Delta$ Np63 $\alpha$ - is essential for ectodermal development in zebrafish, as well as in mammals (3-5). Indeed, the importance of p63 in skin development is shown by mice lacking p63, which die soon after birth with severe defects in limb and craniofacial development and absence of skin. In humans, several syndromes showing abnormalities in limbs, skin and epithelial annexes are caused by missense mutations in the p63 gene (6). p63 is crucial for the activation of the epithelial cell adhesion program (7, 8, reviewed in 9), and it plays a major role in maintaining the proliferative potential of stem cells of the multilayered epithelia (10).

During a profiling screening for p63 targets by RNAi-mediated functional inhibition (11), we identified the High Mobility Group-box protein 1 -HBP1- as a potential target. First identified in rat brain, on the basis of its ability to suppress the potassium transport-defective phenotype of mutant *Saccharomyces cerevisiae* (12), HBP1 was later rediscovered in yeast two hybrids screenings for Rb-interacting proteins (13, 14) and in one hybrid assays for TFs that bind to histone H1 promoters

(15). It is a member of the High Mobility Group protein family, containing a 70 amino-acid HMG box DNA-binding domain that mediates sequence-specific binding. HBP1 was mainly characterized as a transcriptional repressor, a function provided by the central Ataxin -AXH- domain, and an important regulator of cell-cycle exit, apoptosis and terminal differentiation (16). However, transcriptional activation by HBP1 was also reported, notably on the tissue-specific H1, MPO and CD2 promoters (15, 17, 18). Overexpression induces significant changes in the mRNA levels of important TFs involved in differentiation of myeloid cells: C/EBP $\alpha$ , JunB, GATA-1, and RUNX1 are increased, c-Myb, c-Myc, and PU.1 are decreased (19). These changes are in agreement with the idea that HBP1 is a growth suppressive, pro-differentiation TF. In line with this, the gene is induced during differentiation in a variety of tissues and cell types (12, 15, 20, 21), and the protein inhibits cell-cycle progression (15, 20, 21). The molecular mechanisms were also investigated, and direct inhibition of transcriptional activation of Wnt target genes, such as cyclin D1 and c-MYC, was detected (22). Two additional sets of data link HBP1 to growth suppression of tumor cells. First, HBP1 was shown to be required for oncogene-mediated premature senescence, which is a feature that is lost upon malignant transformation (23). Second, Yee *et al.* recently detected two types of HBP1 abnormalities in a large set of breast cancers: the presence of ill-defined variants/mutants and complete lack of expression in a statistically significant number of tumors, indicating a role of HBP1 suppression in the genesis of this type of neoplasia (24).

Essentially nothing is known about the role of HBP1 in keratinocytes and its link to p63. Our interest was enhanced by the finding that p63 has the propensity to target many, if not all TFs genes involved in growth/differentiation decisions. We decided to characterize the relationship between the two TFs, by using a variety of *in vitro* and *in vivo* experiments.

## RESULTS.

### p63 represses HBP1.

Affimetrix microarray profiling of HaCaT cells in which p63 was silenced by siRNA (11) identified HBP1 as a gene repressed by p63. We validated it as a target by RT-PCR in HaCaT and primary normal human epidermal keratinocytes –NHEK- following p63 RNAi: the decrease of p63 led to increase of HBP1 mRNA, compared to cells transfected with the scrambled RNAi; the housekeeping GAPDH was indeed invariant (Fig. 1A). We overexpressed the predominant isoform present in keratinocytes - $\Delta$ Np63 $\alpha$ - as well as TAp63 $\alpha$  and analyzed endogenous HBP1 mRNA levels by semiquantitative RT-PCR (Fig. 1B). To appreciate the overexpression of the transfected genes, we had to limit the cycles of PCR amplifications, which prevented the endogenous levels of p63 to show up: along with the robust overexpression of p63, HBP1 is indeed reduced, particularly with  $\Delta$ Np63 $\alpha$ . We conclude that the HBP1 gene is repressed by p63. To assess whether this is a direct effect, we performed ChIP assays using anti-p63 and control antibodies on the HBP1 promoter region. We selected an amplicon in the core promoter where conservation between human and mouse was high and a consensus p53/p63 was found by bioinformatic means: the anti-p63 antibody was positive in HaCat and NHEK chromatin (Fig. 1C). Finally, we tested the transcriptional effect of the six p63 isoforms on the activity of the HBP1 promoter (-1.2 Kb to +50) fused to a Luciferase reporter, by transiently transfecting NHEK cells. As shown in Fig. 1D, all p63 isoforms efficiently repress the promoter. Altogether, these data indicate that HBP1 is under direct negative regulation of p63 in human keratinocytes.

### Expression of HBP1 in wt, p63 KO mice, and in $\Delta$ Np63 $\alpha$ and TAp63 $\alpha$ transgenics.

To further explore the relationship between p63 and HBP1, we analyzed the expression of HBP1 in the skin of 19.5-days old wt and p63 KO mouse embryos. In wt p63 mice, HBP1 is expressed in the nuclei of the granular and, to some extent, corneum layers, where p63 is not expressed (Fig. 2A,

Left Panels). Some overlap with p63 is evident in the spinous layer. It is also expressed in the derma, which is expected, since the gene is known for having little tissue preference. p63 null mice have scattered skin patches, identified by staining with anti-KRT14, a marker of the basal cells (Fig. 2A, Middle Panels): in addition to the staining in the derma, unaffected by the p63 configuration, we detected high expression of HBP1, proportional to the levels of KRT14. Importantly, HBP1 is nuclear in p63 KO epithelial cells (Fig. 2A, Middle Panels). Finally, we analyzed transgenic mice expressing  $\Delta Np63\alpha$  under the control of the Keratin 5 promoter, in a background of p63 null mice; these mice show some degree of re-epithelialization and re-express several differentiation markers (25). As shown in the Right Panels of Fig. 2A, HBP1 expression is extremely low in the KRT14<sup>+</sup> cells, which are also p63<sup>+</sup> (See Supplementary 1); moreover, in the few positive cells, it is localized in the cytoplasm. The Lower Panels show DAPI staining. To support the Immunofluorescence studies, we performed qRT-PCR of the wt, KO, and mouse skin embryos reconstituted with the  $\Delta Np63$  and TA-p63 isoforms, and of the double transgenics: Fig. 2B shows an increase in HBP1 expression with p63 KO mRNA, compared to wt p63 mice, and a decrease in all the transgenic lines re-expressing p63. Taken together, these data indicate that p63,  $\Delta N$  or TA, is a major negative regulator of HBP1 expression in keratinocytes *in vivo*.

#### HBP1 is activated upon keratinocyte differentiation.

HBP1 has been shown to be regulated in several differentiation systems (12, 15, 20, 21); we wished to ascertain whether this is the case in keratinocytes. NHEK are differentiated *in vitro* by appropriate conditions that include addition of Calcium to the medium: analysis by semi-quantitative RT-PCR indeed shows a substantial increase of HBP1 mRNA after differentiation (Fig. 3A); a marker of upper layers such as KRT1 is up-regulated in differentiated cells, while the basal KRT14 decreases substantially. The invariant NF- $\kappa$ B mRNA was used as an internal control. Next, we monitored by qRT-PCR the kinetics of HBP1 and p63 mRNA during the process: Figure 3B

shows a clear increase in HBP1, whereas p63 decreases, as expected (29). As a control, we also performed Western Blot analysis of keratinocytes differentiation (Supplementary 2, Panel A): multiple bands in addition to the expected 50 kD band are observed, collectively increasing upon differentiation; the decrease in p63 levels is evident, and Loricrin expression levels are induced at the late stages of differentiation. We verified whether p63 binding to the HBP1 promoter is altered during differentiation, by performing ChIPs before and after 7 days of differentiation: Supplementary 2, Panel B shows that p63 is no longer present on the HBP1 promoter after 7 days, in contrast to NF-Y, a CCAAT-binding TF that is bound before and after differentiation. The presence of multiple bands in HBP1 Western blots is in line with genomic annotations, showing the presence of various HBP1 isoforms. To verify this, and check the specificity of the anti-HBP1 antibody, we inactivated HBP1 in primary keratinocytes by siRNA: Supplementary 2, Panel B indicates that all bands, except one, are substantially decreased in extracts of cells transfected with HBP1 siRNA with respect to scramble siRNA. These bands are largely generated by alternative splicing (S. B., R. M., in preparation). Finally, immunofluorescence assays with HBP1 and p63 antibodies confirm the rise of HBP1 protein that matches the decrease in p63 staining over 7 days of differentiation (Fig. 3C). Note that the decrease in p63 levels can only be appreciated at late time points, most likely due to the fact that immunofluorescence is not quantitative. Essentially the same result is obtained in the HaCaT cell line over a period of 3 days (Not shown).

#### HBP1 is required for keratinocyte stratification.

Next, we verified the expression of HBP1 in human interfollicular skin, by Confocal Immunofluorescence using antibodies against p63 and HBP1. Fig. 4A shows that p63 decorates basal cells and progressively fades in the granular and spinous layers; in contrast, HBP1 shows a weak expression in the lower layers, while it is strongly expressed in the cells of the granular layer, where there is some overlap with cells expressing low levels of p63. Most of the expression, however, is



confined to the subcorenum cells, which are p63 negative. The staining of the two proteins is consistent with a negative effect of high p63 levels on expression of HBP1. These results further confirm the reciprocal expression between p63 and HBP1 and suggest that HBP1 might be involved in differentiation of keratinocytes. To ascertain this, we functionally inactivated HBP1 by RNAi in NHEK before and after differentiation, and compared the expression of differentiation markers in cells transfected with scramble siRNA. Fig. 4B shows the qRT-PCR analysis: a substantial decrease of Involucrin and TGM3 was obtained by HBP1 siRNA treatment, particularly after differentiation. On the other hand, the levels of the basal KRT14 drop after differentiation, but no further decrease in HBP1 siRNA-treated NHEK was observed, indicating that this basal marker is not under the control of HBP1. An opposite effect was observed on other markers of differentiation, such as Loricrin, Fillaggrin and KRT1 and 10. All these genes, which are induced during differentiation, show a further increase in their expression in silenced cells. These data suggest that HBP1 inactivation affects differentiation of human keratinocytes, exerting a complex influence, positive and negative, on markers of the upper layers.

In order to confirm the importance of HBP1 in skin homeostasis, we performed a tridimensional organotypic skin reconstitution assay with NHEK transfected with siRNA of HBP1 and Ctl siRNAs. As shown in Fig. 5, tissues regenerated from keratinocytes treated with siHBP1 show impaired stratification compared with siCtl (Upper Panels for Hematoxylin and Eosin stainings). We performed immunofluorescence analysis of Loricrin and observed a significant increase in its expression in epidermis silenced of HBP1 (Fig. 5, lower panels), in agreement with the qPCR analysis performed in Figure 4B. As expected, Loricrin localization in normal human skin sections shows positive staining only in the subcorneum stratum (Unpublished). These data indicate that HBP1 plays a key role in the stratification of human skin in organotypic cultures.

#### Characterization of the HBP1 transcriptome in keratinocytes.

Only a handful genes controlled by HBP1 are known, and the complex effects exerted by removal of HBP1 prompted us to evaluate in an unbiased way the HBP1 dependent transcriptome in keratinocytes. We profiled gene expression of siRNA-inactivated cells. Before that, we performed two types of controls. First, we transfected NHEK cells with siRNA for HBP1 and with a vector coding for HBP1, in parallel: we controlled Wnt signalling targets previously known to be regulated by HBP1. Fig. 6A shows qRT-PCR of c-MYC, c-Jun, CyclinD1 and Sost-DC1 levels: all mRNAs are increased upon HBP1 inactivation, and decreased, with different kinetics, after HBP1 overexpression. Second, we assessed direct HBP1 binding *in vivo* in ChIP assays: Fig.6B indicates the HBP1 is bound to the c-Jun and Cyclin D1 promoters, in an area where potential binding sites are located. Therefore, the alteration of HBP1 levels in keratinocytes directly affects expression of known targets of HBP1.

For profiling, we decided to use the RNAi approach, which is potentially less prone to indirect effects due to the vast overexpression of a TF. To minimize individual variations, we collected primary keratinocytes from three healthy donors and independently transfected them with control and HBP1 siRNA. The levels of HBP1 in these cells were low, yet readily detectable. After evaluation of the levels of HBP1 inactivation, which were greater than 80% (Not shown, See Supplementary 2, Panel C), samples with an equal amount of RNA were pooled and profiling performed on the Illumina platform in triplicate. Considering a threshold of 1.35 over control, 272 genes were upregulated, 48 down-regulated. A list of the regulated genes is shown in Supplementary 3. We validated some of the identified genes by independent RNAi experiments: most showed the expected variation in qRT-PCR analysis (Fig. 7). We noticed that the changes in gene expression measured by qRT-PCR are slightly greater than those recorded by the Illumina expression profiling platform, suggesting that additional genes might have been missed because of the relatively stringent threshold imposed to the analysis. Next, we performed Gene Ontology analysis on the targeted genes, considering terms with p values  $< 10^{-6}$  (Fig. 8). In the Biological Processes, Negative regulation of proliferation and terms related to Development and

Differentiation predominate; in the Cellular Component and Molecular Function analysis, Extracellular space and Secretory functions are enriched. Specifically, many down-regulated genes code for proteins that are involved in barrier function in the upper layers of the skin (See Discussion). This analysis corroborate our findings that HBP1 is an important and complex regulator of the differentiation program in human keratinocytes.

## DISCUSSION.

In this report, we detail the connections between p63 and HBP1 in keratinocytes. Originally emerging from an RNAi profiling screening, HBP1 has been confirmed as a direct target of p63 by several criteria, *in vitro* and *in vivo*. HBP1 is important for skin differentiation and profiling analysis confirms that it partakes in a program of advanced differentiation and stratification.

### p63 inhibits a potent growth suppressor.

Key to our understanding of the strategy of TFs in regulating cellular functions is the identification of targets. The p63 network in keratinocytes was identified by two strategies, gene expression profiling of p63-depleted cells (7, 8, 11, 26, 27) and ChIP on chip (28-30). Genes involved in growth, adhesion and transcriptional regulation are the most significant GO terms enriched.

Essentially, TFs involved in all pathways known to play a role in differentiation -Notch, TGF $\beta$ , Wnt/ $\beta$ -catenin, nuclear receptors, SH, C/EBPs- are under direct p63 regulation (30). A network of reciprocal interplay is emerging, which fine tunes and adapts the relative levels of the TFs involved to the various external conditions. p63 has well established pro-growth activities that regulate stem cell potential of pluristratified epithelia; in addition, it is involved in the establishment of the stratification program in the embryo, but it is currently debated whether it partakes in all phases of differentiation, including cornification (31). Simple considerations concerning the levels of p63 expression in the different skin layers suggest that it is involved in the growth of proliferating and early differentiating lower layers of epidermis. As these cells mature, other TFs are predominantly expressed, with essentially two missions: promote expression of differentiation genes eventually involved in barrier formation, and exit from the cell-cycle. IRF6, Ikk $\alpha$ , Gata3 and C/EBP $\delta$  are p63 targets with these effects (32-37), and our data indicate that HBP1 joins this list, as determined by

ChIP, RNAi, overexpression, transient Luciferase assays and evaluation of HBP1 levels in wt, p63 KO and transgenics. It is worth noting that in this latter context, HBP1 levels are mainly controlled by the levels of p63, while other p63 targets, such as EGF-R, show independence from p63 levels, suggesting that they are controlled by other important TFs. The strong and dominant repressive effect of p63 on HBP1 is consistent with the growth-suppressive role of the latter. In this scenario, p63 would have to down-play all other TFs that interfere with growth and promote terminal differentiation. Interestingly, unlike many other TFs, inactivation of HBP1 leads to essentially no alteration in the levels of p63, indeed suggesting that the latter is acting upstream of HBP1 in the differentiation cascade, and that p63 down regulation, which is observed in the upper layers, is exerted through different mechanisms.

#### HBP1 in keratinocyte differentiation and stratification.

The discovery of HBP1 was followed by several papers reporting that the gene is induced in many differentiation systems, including muscle, hematopoietic cells and adipocytes (12, 15, 20, 21). The process takes a few days to complete: whenever measured, the kinetics of induction of HBP1 were relatively fast -within a few hours- and lasted 12-18 hours maximum, consistent with a relatively early role in the process. In muscle cells, inactivation of HBP1 by siRNA was matched by lack, or reduced, differentiation (20). The repressive activities of HBP1 are believed to be responsible for the repression of G1/S genes by recruitment of Rb and pocket proteins, and their associated histone modifying complexes (16). However, our ChIP data is the first direct evidence that this mechanism is operational *in vivo via* direct sequence-specific promoter interactions. Furthermore, the capacity to interfere with key genes activated by Wnt signalling, regulated through TCFs, induces withdrawal from the cell cycle and differentiation. The keratinocytes data are consistent with these observations, in terms of kinetics of induction (Fig. 3), expression levels in suprabasal layers of human and mouse skin (Figs. 2 and 4), requirement of HBP1 to complete the process of

differentiation and stratification (Fig 5). The vastly impaired stratification of skin sections inactivated of HBP1 is currently the first example of the importance of HBP1 for tissue differentiation. The role of HBP1 is evidently complex, since some markers of differentiation, such as TGM3 and Involucrin are reduced, while Loricrin is increased, both in the primary culture and in the tridimensional systems: hence the need for transcriptome analysis.

The list of HBP1 regulated genes is very informative of the role of HBP1 in keratinocytes (Fig. 8). Enriched GO terms such as Regulation of epithelial differentiation, Epidermis development and regulation of epithelial proliferation were expected and they are reassuringly at the top of the list. We find fewer genes whose expression is decreased after RNAi, than genes that are increased, confirming that this TF is primarily a repressor. However, HBP1-activated genes exist and many of them do play a role in differentiation (Fig. 9). One of these is SPRRs, a member of a large cluster of genes whose expression is coordinated (38, 39): Small Proline-Rich proteins are primary constituents of the Stratum Corneum (SC), expressed in the granular layer, with no staining in the spinous or basal layers. SPINK proteins are serine protease inhibitors of the Kazal type, also involved in skin barrier formation. In fact, mutations in the Spink5 (LEKTI) gene cause the Netherton syndrome, characterized by ichthyosiform dermatosis and hair shaft abnormalities (40, 41) and Spink5 KO mice have severe alteration in the SC (42-44). Additional activated targets are COX-2, FLH1 and ROBO3. COX-2 is expressed in the upper layer and is involved in differentiation (45). FHL1, also known as KyoT1/2 or SLIM1, is a LIM domain transcriptional coactivator whose expression suppresses differentiation: it modulates Notch and TGF $\beta$  signalling, through interactions with RBP-J and SMADs, respectively (46, 47). Thus, the link with this TF could expand the consequences of HBP1 modulation to two important pathways, which are also affected directly by p63 (48). Opposite regulation is observed for the Spink1-Furin complex and for other Spink targets, the Kallikreins-related peptidases, KLKs: specifically, Furin is a subtilysin-like convertase abundantly expressed in epidermal keratinocytes and involved in differentiation (49), KLK4 and KLK14 are serine proteases implicated in the desquamation process of the skin (50-52).

TGM5 is a transglutaminase, whose mutation is associated with the Acral Peeling Skin Syndrome (53). Thus, fine tuning of proteases and inhibitors in upper layers is apparently a major task of HBP1. Additional coregulation is observed for ROBO3, a transmembrane receptor, and for one of its ligands, SLIT1 (54).

As for repressed genes, there are several genes of the Wnt pathway: in addition to c-Jun and c-Myc, SFRP1, SPON2, UNC5B, PKP2, COX2 are new targets (55-61). Recent data reported in breast cancer indicate that HBP1 is structurally altered, through poorly identified mechanisms, in 16% of tumors, and specifically silenced in the majority of aggressive tumors (24). Indeed, the lack of HBP1 expression is of high prognostic value, together with that of SFRP1, as markers of relapse and poor prognosis. SFRP1 is a negative regulator of Wnt signalling: the notion that HBP1 controls SFRP1 levels is consistent with a tumor suppressive function of the former. In this respect, it will be interesting to ascertain whether a direct functional link is present in breast cells as well, and whether HBP1 and SFRP1 levels are also reduced in metastatic skin cancers. COX-2 is another gene whose altered levels are associated with breast malignancies (61) and Paulson et al. indeed hypothesized that COX-2 overexpression is an indirect effect of HBP1 inactivation (24). In line with a growth suppressive function of HBP1 is the repression of a number of growth promoting genes, such as PDGF $\beta$ 2, CDK6, E2F2, Id1, EGR2/KROX20, HOXA5, SPARC, all expressed in lower skin layers (62-67), or LIF, expressed in the granular layer (68, 69), as well as MMP9, a metalloprotease involved in metastasis, and TMPRSS4, involved in Epithelial Mesenchymal Transition, EMT (70, 71). Finally, while there are no data on TIP30 in the skin, overexpression of this gene stimulates, and inactivation represses, metastasis of prostate cancer cells (72).

Intriguingly, there are two groups of genes whose repression is apparently at odd with a simplistic model of HBP1 as an anti-growth, pro-differentiation TF. The first relates to several repressed genes specifically expressed in the upper layers: KRT1 and KRT4, as well as KRT9, a location specific cytokeratin expressed in palmoplantar epidermis (73, 74); Loricrin and Filaggrin, terminal differentiation markers, and S100A7 (Psoriasin), which is expressed in the superficial,

differentiated cells and whose expression is altered in psoriatic skin (75). SLIT1 and RARRES1-3 (also known as TIG1-3) are also involved in differentiation (76). Claudin-8 is a component of tight junctions (77). It is possible that HBP1 repression of these genes is a matter of proper timing during terminal differentiation, and that other TFs are directly involved in relieving the early HBP1-repression post cell-cycle block, to activate this class of genes.

The second is a group of genes that are notoriously associated with growth suppression, in keratinocytes and other cell types: SPRX/Dro1 (78), the p53 targeted antioxidants SESN3 and SULF2 (79, 80), Edg-8 (81). p21 and p16INK4, are also in this class. The former was previously identified as a target (82); a possible explanation as to the significance of this class comes from inactivation of p16INK4, which allows primary keratinocytes to escape replicative senescence, apparently maintaining keratinocytes in the stem cell compartment (83). p16INK4 downregulation in Transient Amplifying keratinocytes, instead, has no effects. Thus, p16INK4 appears to control epidermal stem cells. Could this point to a role of HBP1 in restricting growth in basal layers stem cells, as it has been proposed for C/EBP $\delta$  in corneal epithelia (36)? Interestingly, a recent study has identified p16INK4 as a gene repressed by p63 *in vivo*, in elegant rescue experiments with KO mice (84). Our data, showing repression of p16INK4 by HBP1, suggest that this growth suppressor might be the focus of important convergent signals between the two TF. In general, the cohort of genes that are under mutual control is quite significant, with variation depending from the source of p63 targets considered (Summarized in Supplementary 4): overall 80 out of 320 genes regulated by HBP1 are found in one, or more lists of p63 targets.

Finally, two targeted TFs appear to play important regulatory roles during development, which might be related to p63 function. (i) Strong HOXA4 expression is detected in the basal layer of Day 10 mice fetal epidermis (66): incidentally, this timing correlates with the onset of p63 expression and with epidermal stratification. In newborn and adult life, expression of HOXA4 moves up to the granular layer of newborn and adult mice skin, suggesting that this TF might be important for the initial stratification program and for further differentiation in adult life. (ii) The



Leucine zipper c-maf is first expressed on embryonic Day 16 in the basal layer of epidermis, increases until D19 and by postnatal Day 3 expression disappears (84), suggesting that it might be involved in the maintenance of proliferative potential in the embryonic period.

In summary, our work identifies HBP1 as an important hub in decisions making during keratinocyte differentiation, that is targeted negatively by p63; it also defines two classes of genes involved in terminal differentiation that are differentially regulated by HBP1. Future studies on the network of HBP1 targets should aim at clarifying their role in normal conditions and neoplastic transformation, as the network of regulated genes might be altered in expression in specific tumors.

## **ACKNOWLEDGEMENTS.**

We thank T. Kouzarides (Cambridge, UK) for kindly providing the HBP1 plasmids. This work was supported by grants from European Union (EPISTEM LSHB-CT-2005-019067 to R.M., GP.D. and G.M., and CRESCENDO LSHM-CT-2005-018652 to A.W.), CARIPLO to R.M., MIUR (PRIN) and Associazione Italiana per la Ricerca sul Cancro, to R.M. and A.W. S.B. has a fellowship from the U degli Studi di Milano. O.M.V. Grober is a student of the PhD School in Environment, Biological, Biotechnology, Physics, Mathematics and Informatics Sciences/Doctorate in Pathology of Cell Signal Transduction; M. Ravo is a student of the PhD School in Toxicology/Doctorate in Molecular Oncology and Molecular Pathology, University of Cagliari (Italy).

## MATERIALS AND METHODS.

**Cells and culture conditions.** HaCaT were grown in DMEM in the presence of 10% foetal calf serum. First passage primary human keratinocytes -NHEK- were derived from breast of healthy individuals and grown on a feeder-layer of lethally irradiated 3T3 cells in DMEM F12 added of Insulin (5 µg/ml), EGF-R (10 ng/ml) hydrocortisone (0.4 µg/ml), T3 (2 nM), Cholera toxin (0.1 nM) and transferrin (5 µg/ml). NHEK were differentiated by adding CaCl<sub>2</sub> (1.4 mM final concentration) in the presence of 10% foetal calf serum, HaCaT by adding calcium and lowering FCS to 0.1%.

**3D human keratinocyte culture.** The cultured is based on Millicell hanging cell culture insert, (polyethylene terephthalate, 1.0 µm, Millipore). Early passage (passage 2) human keratinocytes were seeded at a density of 50,000/insert in 0.2ml expansion medium (CNT-07, Cellntec, Berne, Switzerland). The inserts were then placed in 12 well plate with 1 ml CNT-07 medium added into the well. The culture was maintained for 8 hours at 37 °C, 5% CO<sub>2</sub> before siRNA transfection.

**RT-PCR, q-PCR and transfections.** HaCaT cells were transiently trasfected using Oligofectamine (Gibco-BRL, USA) for three hours with 150 ng/cm<sup>2</sup> of human p63 siRNA oligonucleotide which targets the central DNA-binding domain of p63 (11). After overnight incubation, transfection was repeated for 3 additional hours. 2.5 x10<sup>5</sup> first passage NHEK were transfected with Nucleofector (Amaza, D) using siRNA ologonucleotides at 0.5 nM. p63 inactivation was described in Refs 11 and 37. The HBP1 siRNA was 5'-GCUUGACUGUGGUACAGCAtt-3', 5'-UGCUGUACCACAGUCAAGCtt-3' (Ambion, USA); an off-target siRNA oligos mixture (5'-AUGAACGUGAAUUGCUCAA-3', 5'-UAAGGCUAUGAAGAGAUAC-3', 5'-AUGUAUUGGCCUGUAUUAG-3', 5'-UAGCGACUAAACACAUCAA-3'; Dharmacon D-00181001) was used as control. RNA was extracted with RNA-Easy kit (Qiagen, D), 48 hours after siRNA transfections. For cDNA synthesis, 4ug of RNA were retrotranscribed with M-MLV-RT kit (Invitrogen, USA). Semi-quantitative PCR analysis was performed with primers listed in

Supplementary 5. For q-PCR, a Biorad MyIQ single colour thermal cycler and a SYBR Green PCR Master mix were used. Specificity of products was monitored with a heat dissociation curve. Fold changes of expression were calculated with the formula  $2^{-\Delta Ct}$  where the Ct represented the threshold cycles of the specific gene and GAPDH. The HBP1 promoter (-1200 +50) was PCR-amplified with Pfu polymerase (Genespin, I) and cloned into XhoI BglII sites of pGL3-Basic-Luciferase. For transactivation experiments,  $1 \times 10^5$  NHEK cells were transfected with Lipofectamine (Gibco-BRL) using 1.2  $\mu$ g of HBP1-Luciferase reporter plasmid, 200 ng of p63 different splicing isoforms, and carrier for a total DNA of 2  $\mu$ g. Four independent transfections in duplicate were performed.

RNAi in 3D system: For siRNA transfection, for each well, 120 pmoles of siRNA duplexes and controls were diluted into 200  $\mu$ l of CNT-07 medium then were mixed with 10  $\mu$ l of INTERFERin (Polyplus, Illkirch, France) for 10 minutes at room temperature. Then the 200  $\mu$ l of transfection mix were added into the inserts to replace the previous medium in it. The achieved final siRNA concentration is 100nM. The cells were maintained in CNT-07 medium for 48-72 hours till 100% confluence. The culture medium was then into 3D medium (CNT-02-3DP5, Cellntec, Berne, Switzerland). After 16 hours, the medium in the insert was aspired and the cells were exposed to air. In the meantime, the medium in the wells was refreshed. The 3D culture was then maintained for 7 days by changing the medium every day. After that the samples were collected for immunohistological analysis and RNA extraction. All the samples were performed at duplex.

**Chromatin immunoprecipitations.** ChIP analysis were carried out as previously described by Ref. 29, with 5  $\mu$ g of anti-p63 antibody (Genespin, I), 5  $\mu$ g of HBP1 antibody (Active Motif, USA) and 5  $\mu$ g of Flag control antibody (Sigma, USA). The list of primers used in the PCR amplifications are in Supplementary 5.

**Immunofluorescence and Immunohistochemistry.** Immunofluorescence analysis was performed as in Ref. 29 with the following antibodies: p63 (Genespin, I), HBP1 (Active Motif, USA), KRT14

(Neomarkers, USA). For IHC, 14  $\mu$ M paraffin sections were deparaffined and then blocked for 60min in PBST (0.1% Triton X100 in PBS) with 2.5 % donkey serum, 2.5% goat serum, 0.5% cold water fish gelatin, and 0.5% BSA. Primary antibodies were applied for 16 hours at 4°C and secondary antibodies were applied for 1 hour at room temperature. DAPI nuclei counterstaining was used.

**RNA profiling.** NHEK cells from three independent healthy donors were transfected by Lipofectamine (Gibco-BRL) with scramble and HBP1 siRNA. Cells were harvested after 48 hours and RNA prepared with the RNA-Easy kit. RNA concentrations were determined with a Nanodrop (NanoDrop, USA) spectrophotometer and quality was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies). 2  $\mu$ g of each sample were pooled, for further processing. For each sample, 500 ng of total RNA were synthesized to biotinylated cRNA using the Illumina RNA Amplification Kit (Ambion, USA). Synthesis was carried out according to the manufacturers' instructions. cRNA concentration and the quality were assessed out as described above. From each sample, technical replicates were produced and 750 ng cRNA were hybridized for 18hrs to HumanHT12 v. 3.0 Expression BeadChips (Illumina Inc., USA) according to the protocol provided by the manufacturer. Hybridized chips were washed and stained with streptavidin-conjugated Cy3 (GE Healthcare, USA). BeadChips were dried and scanned with an Illumina BeadArray Reader (Illumina Inc.,USA).

For data analysis, the intensity files were loaded into the Illumina BeadStudio v. 3.1.3.0 software for quality control and gene expression analysis. First, the quantile normalization algorithm was applied on the dataset to correct systematic errors. Background is subtracted. For differential expression analysis, technical replicates of each sample were grouped together and genes with a detection p-value below 0.01, corresponding to a false positive rate of 1%, were considered as detected. Differently expressed genes were selected with Diff Score cutoff set at  $\pm 30$ , corresponding to a p-value of 0.001.

## REFERENCES.

1. Aylon Y, Oren M. Living with p53, dying of p53. *Cell* 2007; **130**:597-600.
2. McKeon F. p63 and the epithelial stem cell: more than *status quo*? *Genes Dev.* 2004; **18**:465-469.
3. Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. *Dev Cell.* 2002; **2**:607-616.
4. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature* 1999; **398**:708-713.
5. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature* 1999; **398**:714-718.
6. Rinne T, Hamel B, van Bokhoven H, Brunner HG. Pattern of p63 mutations and their phenotypes--update. *Am J Med Genet A.* 2006; **140**:1396-1406.
7. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. *Nat Cell Biol.* 2006; **8**:551-561.
8. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. *Cancer Res.* 2006; **66**:7589-97.
9. Carroll DK, Brugge JS, Attardi LD. p63, cell adhesion and survival. *Cell Cycle* 2007; **6**:255-261.
10. Senoo M, Pinto F, Crum CP, McKeon F. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. *Cell* 2007; **129**:523-536.
11. Testoni B, Borrelli S, Tenedini E, Alotto D, Castagnoli C, Piccolo S, et al. Identification of new p63 targets in human keratinocytes. *Cell Cycle* 2006; **5**:2805-2811.
12. Lesage F, Hugnot J-P, Amri E-Z, Grimaldi P, Barhanin J & Lazdunski M. Expression cloning

in K<sup>+</sup> transport defective yeast and distribution of HBP1, a new putative HMG transcriptional regulator. *Nucleic Acids Res.* 1994; **22**:3695–3688.

13. Tevosian SG, Shih HH, Mendelson KG, Sheppard KA, Paulson KE, Yee AS. HBP1: a HMG box transcriptional repressor that is targeted by the retinoblastoma family. *Genes Dev.* 1997; **11**:383-396.

14. Lavender P, Vandel L, Bannister AJ, Kouzarides T. The HMG-box transcription factor HBP1 is targeted by the pocket proteins and E1A. *Oncogene* 1997; **14**:2721–2728.

15. Lemerrier C, Duncliffe K, Boibessot I, Zhang H, Verdel A, Angelov D, Khochbin S. Involvement of retinoblastoma protein and HBP1 in histone H1(0) gene expression. *Mol Cell Biol.* 2000; **20**:6627–6637.

16. Yee, AS, Paulson, EK, McDevitt, MA, Rieger-Christ K, Summerhayes I, Berasi SP. et al. The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression. *Gene* 2004; **336**:1-13.

17. Lin KM, Zhao WG, Bhatnagar J, Zhao WD, Lu JP & Simko S et al. Cloning and expression of human HBP1, a high mobility group protein that enhances myeloperoxidase (MPO) promoter activity. *Leukemia* 2001; **15**: 601–612.

18. Zhuma T, Tyrrell R, Sekkali B, Skavdis G, Saveliev A, Tolaini M, et al. Human HMG box transcription factor HBP1: a role in hCD2 LCR function. *EMBO J.* 1999; **18**:6396–6406.

19. Yao CJ, Works K, Romagnoli PA, Austin GE. Effects of overexpression of HBP1 upon growth and differentiation of leukemic myeloid cells. *Leukemia* 2005; **19**:1958-1968.

20. Shih H, Tevosian SG, Yee AS. Regulation of differentiation by HBP1, a target of the retinoblastoma protein. *Mol Cell Biol.* 1998; **18**:4732–4743.

21. Shih HH, Xiu M, Berasi SP, Sampson EM, Leiter A, Paulson KE, Yee AS. et al. HMG box transcriptional repressor HBP1 maintains a proliferation barrier in differentiated liver tissue. *Mol Cell Biol.* 2001; **21**:5723–5732.

22. Sampson EM, Haque ZK, Ku MC, Tevosian SG, Albanese C, Pestell RG et al. Negative

- regulation of the Wnt- $\beta$ -catenin pathway by the transcriptional repressor HBP1. *EMBO J.* 2001; **20**:4500–4511.
23. Zhang X, Kim J, Ruthazer R, McDevitt MA, Wazer DE, Paulson KE, Yee AS. The HBP1 transcriptional repressor participates in RAS-induced premature senescence. *Mol Cell Biol.* 2006; **26**:8252–66.
24. Paulson KE, Rieger-Christ K, McDevitt MA, Kuperwasser C, Kim J, Unanue VE, et al. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer. *Cancer Res.* 2007; **67**:6136-45.
25. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A, De Laurenzi V, Spagnoli LG, Catani MV, Ramadan S, Knight RA, Melino G. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. *Cell Death Differ.* 2006; **13**:1037-1047.
26. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. *Genes Dev.* 2006; **20**:3185-3197.
27. Viganò MA and Mantovani R. Hitting the numbers: the emerging network of p63 targets. *Cell Cycle* 2007; **6**:233-239.
28. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. *Mol Cell* 2006; **24**:593-602.
29. Viganò MA, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C, et al. New p63 targets in keratinocytes identified by a genome-wide approach. *EMBO J.* 2006; **25**:5105-5116.
30. Pozzi S, Zambelli F, Merico D, Pavesi G, Gidrol X, Mantovani R, Viganò MA. Transcriptional network of p63 in human keratinocytes. *PLoS ONE* 2009; **4**:e5008.
31. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. *Nat Rev Mol Cell Biol.* 2005; **6**:328-340.
32. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M, Roop DR. p63 induces key

- target genes required for epidermal morphogenesis. *Proc Natl Acad Sci USA* 2007; **104**:3255-3260.
33. Richardson RJ, Dixon J, Malhotra S, Hardman MJ, Knowles L, Boot-Handford RP et al. Irf6 is a key determinant of the keratinocyte proliferation differentiation switch. *Nat Genet.* 2006; **38**:1329-1334.
34. Ingraham CR, Kinoshita A, Kondo S, Yang B, Sajan S, Trout KJ, et al. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). *Nat Genet.* 2006; **38**:1335-40.
35. Chikh A, Sayan E, Thibaut S, Lena AM, DiGiorgi S, Bernard BA, et al. Expression of GATA-3 in epidermis and hair follicle: relationship to p63. *Biochem Biophys Res Commun.* 2007; **361**:1-6.
36. Barbaro, V., A. Testa, Di Iorio E, Mavilio F, Pellegrini G, De Luca M. C/EBPdelta regulates cell cycle and self-renewal of human limbal stem cells. *J Cell Biol.* 2007; **177**:1037-1049.
37. Borrelli S, Testoni B, Callari M, Alotto D, Castagnoli C, Romano R-A et al.. Reciprocal regulation of p63 by C/EBPdelta in human keratinocytes. *BMC Mol. Biol.* 2007; **8**:85.
38. Koizumi H, Kartasova T, Tanaka H, Ohkawara A, Kuroki T. Differentiation-associated localization of small proline-rich protein in normal and diseased human skin. *Br J Dermatol.* 1996; **134**:686-692.
39. Martin N, Patel S, Segre JA. Long-range comparison of human and mouse Sprr loci to identify conserved noncoding sequences involved in coordinate regulation. *Genome Res.* 2004; **14**:2430-2438.
40. Zeeuwen PL. Epidermal differentiation: the role of proteases and their inhibitors. *Eur J Cell Biol.* 2004; **83**:761-773.
41. Mägert HJ, Kreutzmann P, Drögemüller K, Ständker L, Adermann K, Walden M et al. The 15-domain serine proteinase inhibitor LEKTI: biochemical properties, genomic organization, and pathophysiological role. *Eur J Med Res.* 2002; **7**:49-56.



42. Yang T, Liang D, Koch PJ, Hohl D, Kheradmand F, Overbeek PA. Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosin in *Spink5*<sup>-/-</sup> mice. *Genes Dev.* 2004; **18**:2354-2358.
43. Hewett DR, Simons AL, Mangan NE, Jolin HE, Green SM, Fallon PG, McKenzie AN. Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. *Hum Mol Genet.* 2005; **14**:335-346.
44. Descargues P, Deraison C, Bonnart C, Kreft M, Kishibe M, Ishida-Yamamoto A et al. *Spink5*-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. *Nat Genet.* 2005; **37**:56-65.
45. Leong J, Hughes-Fulford M, Rakhlin N, Habib A, Maclouf J, Goldyne ME. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. *Exp. Cell Res.* 1996; **224**:79–87.
46. Qin H, Wang J, Liang Y, Taniguchi Y, Tanigaki K, Han H. RING1 inhibits transactivation of RBP-J by Notch through interaction with LIM protein KyoT2. *Nucleic Acids Res.* 2004; **32**:1492–1501
47. Grossi M, Hiou-Feige A, Tommasi Di Vignano A, Calautti E, Ostano P et al. Negative control of keratinocyte differentiation by Rho/CRIK signaling coupled with up-regulation of KyoT1/2 (FHL1) expression. *Proc Natl Acad Sci USA* 2005; **102**:11313-11318.
48. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G et al. Crossregulation between Notch and p63 in keratinocyte commitment to differentiation. *Genes Dev.* 2006; **20**:1028-1042.
49. Pearton DJ, Nirunsuksiri W, Rehemtulla A, Lewis SP, Presland RB, Dale BA. Proprotein convertase expression and localization in epidermis: evidence for multiple roles and substrates. *Exp Dermatol.* 2001; **10**:193–203.
50. Komatsu N, Takata M, Otsuki N, Toyama T, Ohka R, Takehara K, Saijoh K. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. *J Invest*

*Dermatol.* 2003; **121**:542-549.

51. Emami N, Diamandis EP. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. *J Biol Chem.* 2008; **283**:3031-3041.

*Biol Chem.* 2008; **283**:3031-3041.

52. Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pHdependent interaction. *Mol Biol Cell.* 2007; **18**:3607-3619.

53. Cassidy AJ, van Steensel MA, Steijlen PM, van Geel M, van der Velden J, Morley SM, Terrinoni A, Melino G, Candi E, McLean WH. A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome. *Am. J. Hum. Genet.* 2005; **77**:909-17.

54. Hohenester E. Structural insight into Slit-Robo signalling. *Biochem Soc Trans.* 2008; **36**:251-256.

55. Zhang Y, Andl T, Yang SH, Teta M, Liu F, Seykora JT et al. Activation of beta-catenin signaling programs embryonic epidermis to hair follicle fate. *Development* 2008; **135**:2161-2172.

56. Yang L, Yamasaki K, Shirakata Y, Dai X, Tokumaru S, Yahata Y et al. Bone morphogenetic protein-2 modulates Wnt and frizzled expression and enhances the canonical pathway of Wnt signaling in normal keratinocytes. *J Dermatol Sci.* 2006; **42**:111-119.

57. Kazanskaya O, Glinka A, del Barco Barrantes I, Stannek P, Niehrs C, Wu W. R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for *Xenopus* myogenesis. *Dev Cell* 2004; **7**:525-534.

58. McGrath JA, Wessagowit V. Human hair abnormalities resulting from inherited desmosome gene mutations. *Keio J. Med.* 2005; **54**:72-79.

59. Zhang Y, Andl T, Yang SH, Teta M, Liu F, Seykora JT et al. Activation of beta-catenin signaling programs embryonic epidermis to hair follicle fate. *Development* 2008; **135**:2161-

2172.

60. Cowling VH, Cole MD. Turning the tables: Myc activates Wnt in breast cancer. *Cell Cycle* 2007; **6**:2625-2627.

61. Neufang G., Furstenberger G., Heidt M., Marks F., Muller-Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. *Proc. Natl. Acad. Sci. USA*. 2001; **98**:7629–7634.

62. Grose R, Harris BS, Cooper L, Topilko P, Martin P. Immediate early genes *krox-24* and *krox-20* are rapidly up-regulated after wounding in the embryonic and adult mouse. *Dev Dyn*. 2002; **223**:371-378.

63. Longworth MS, Wilson R, Laimins LA HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. *EMBO J*. 2005; **24**:1821-1830.

64. Rotzer D, Krampert M, Sulyok S, Braun S, Stark HJ, Boukamp P, Werner S. Id proteins: novel targets of activin action, which regulate epidermal homeostasis. *Oncogene* 2006; **25**:2070-2081.

65. Langlands K, Down GA, Kealey T. Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell carcinoma. *Cancer Res*. 2000; **60**:5929-5933.

66. Stelnicki EJ, Kömüves LG, Kwong AO, Holmes D, Klein P, Rozenfeld S, et al. HOX homeobox genes exhibit spatial and temporal changes in expression during human skin development. *J Invest Dermatol*. 1998; **110**:110-115.

67. Ford R, Wang G, Jannati P, Adler D, Racanelli P, Higgins PJ, Staiano-Coico L. Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. *Exp Cell Res*. 1993; **206**:261-275.

68. Szepietowski JC, Reich A, McKenzie RC. The multifunctional role of leukaemia inhibitory factor in cutaneous biology. *Acta Dermatovenereol Alp Panonica Adriat*. 2004; **13**:125-129.

69. Paglia D, Kondo S, Ng K-ME, Sauder DN, McKenzie RC. Leukaemia inhibitory factor is

- expressed by normal keratinocytes in vitro and in vivo. *Br J Dermatol.* 1996; **34**:817-823.
70. Yagi R, Waguri S, Sumikawa Y, Nada S, Oneyama C, Itami S et al. C-terminal Src kinase controls development and maintenance of mouse squamous epithelia. *EMBO J.* 2007; **26**:1234-1244.
71. Choi SY, Shin HC, Kim SY, Park YW. Role of TMPRSS4 during cancer progression. *Drug News Perspect.* 2008; **21**:417-423.
72. Zhang H, Zhang Y, Duan HO, Kirley SD, Lin SX, McDougal WS et al. TIP30 is associated with progression and metastasis of prostate cancer. *Int J Cancer* 2008; **123**:810-816.
73. Jenkins TD, Opitz OG, Okano J, Rustgi AK. Transactivation of the human keratin 4 and Epstein-Barr virus ED-L2 promoters by gut-enriched Krüppel-like factor. *J Biol Chem.* 1998; **273**:10747-10754.
74. Tanioka M, Miyagawa-Hayashino A, Manabe T, Toichi E, Miyachi Y, Takahashi K. Circumscribed palmo-plantar hypokeratosis: a disease with two subtypes. *J Invest Dermatol.* 2009; **129**:1045-7.
75. Martinsson H, Yhr M, Enerbäck C. Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. *Exp Dermatol.* 2005; **14**:161-168.
76. Eckert RL, Sturniolo MT, Jans R, Kraft CA, Jiang H, Rorke EA. TIG3: a regulator of type I transglutaminase activity in epidermis. *Amino Acids* 2009; **36**:739-46.
77. Yu AS, Enck AH, Lencer WI, Schneeberger EE. Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation. *J. Biol. Chem.* 2003; **278**:17350-17359.
78. Bommer GT, Jäger C, Dürr EM, Baehs S, Eichhorst ST, Brabletz T et al. DRO1, a gene downregulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells. *J Biol Chem.* 2005; **280**:7962-7975.
79. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. *Cell* 2008; **134**:451-460.

80. Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrenner P et al. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. *Cancer Res.* 2009; **69**:1368-1374.
81. Vogler R, Sauer B, Kim DS, Schäfer-Korting M, Kleuser B. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. *J Invest Dermatol.* 2003; **120**:693-700.
82. Gartel AL, Goufman E, Tevosian SG, Shih H, Yee AS, Tyner AL. Activation and repression of p21(WAF1/CIP1) transcription by RB binding proteins. *Oncogene* 1998; **17**:3463-3469.
83. Maurelli R, Zambruno G, Guerra L, Abbruzzese C, Dimri G, Gellini M et al. Inactivation of p16INK4a (inhibitor of cyclin-dependent kinase 4A) immortalizes primary human keratinocytes by maintaining cells in the stem cell compartment. *FASEB J.* 2006; **20**:1516-1518.
84. Su X, Cho MS, Gi YJ, Ayanga BA, Sherr CJ, Flores ER. Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. *EMBO J.* 2009; **28**(13):1904-15
85. Ogata A, Shimizu T, Abe R, Shimizu H, Sakai M. Expression of c-maf and mafB genes in the skin during rat embryonic development. *Acta Histochem.* 2004; **106**:65-67.
86. A. Yang, Z. Zhu, P. Kapranov, F. McKeon, G. Church, T. Gingeras, K. Struhl. Relationships between p63 Binding, DNA Sequence, Transcription Activity, and Biological Function in Human Cells. *Molecular Cell* 2006; **24**:593-602.
87. Della Gatta G, Bansal M, Ambesi-Impiombato A, Antonini D, Missero C, di Bernardo D. Direct targets of the TRP63 transcription factor revealed by a combination of gene expression profiling and reverse engineering. *Genome Res.* 2008; **18**:939-948.

## FIGURE LEGENDS.

### **Figure 1.** HBP1 is a target of p63.

**A.** Expression analysis of the indicated genes in HaCaT and NHEK cells, treated with siRNA p63 or scramble oligo (Ctl). Upper Panels, RT-PCR with RNA extracted from HaCaT;  $\beta$ -actin was used to normalize cDNA. Lower Panel, RT-PCR with RNA extracted from NHEK; GAPDH was used to normalize. **B.** p63 overexpression in NHEK. RT-PCR analysis of the indicated genes with RNA extracted from NHEK 48 hours after transient transfection with  $\Delta$ Np63 $\alpha$  and TAp63 $\alpha$  expression plasmids. The normalization of the cDNAs was performed with GAPDH. **C.** Chromatin Immunoprecipitation analysis of HaCaT (upper Panel) and NHEK (lower Panel) with  $\alpha$ -p63 and control  $\alpha$ -Flag antibodies on the HBP1 promoter. The lower chart is a schematic representation of the HBP1 promoter locus, with black and grey dots indicating *in silico* p63 and p53 sites, respectively, in the appropriate position. Displayed is also the mouse conservation from CONSITE. The black bar indicates the region amplified in the ChIP experiments. **D.** Transactivation assay in NHEK cells. Transcription activity of the different p63 isoforms cotransfected with the human HBP1 promoter. Bars represent the Luciferase activity ( $\pm$  SD), expressed as repression of the promoter activity cotransfected with an empty vector (Ctl).

### **Figure 2.** Expression of HBP1 in wt, p63 KO mice, $\Delta$ Np63 $\alpha$ and TAp63 $\alpha$ transgenics.

**A.** Left Panels, Confocal images of mouse embryo skin immunostained with p63 (green) and HBP1 (red). Middle Panels, p63<sup>-/-</sup> mouse skin immunostained with KRT14 (green) and HBP1 (red). Right Panels,  $\Delta$ Np63-Tg mice immunostained with KRT14 (green) and HBP1 (red). The Bottom Panels in each conditions represent DAPI stainings. **B.** qRT-PCR of mRNA extracted from the embryo skin of wt, p63 KO mice, and from transgenics reconstituted with  $\Delta$ Np63 $\alpha$ , TAp63 $\alpha$  and  $\Delta$ N-TAp63 $\alpha$  genes under the control of the KRT5 promoter (See Ref. 25).

**Figure 3. HBP1 is activated upon keratinocyte differentiation.**

**A.** Semiquantitative analysis of KRT1, KRT14, HBP1 and of the invariant control NF-YB, in growing and differentiated NHEK. **B.** Kinetics analysis of  $\Delta$ Np63 and HBP1 expression by qRT-PCR after 2, 3 and 7 days (2D, 3D, 7D) of differentiation. **C.** Confocal Immunofluorescence analysis of p63 and HBP1 expression in NHEK, after the indicated time following the differentiation stimulus.

**Figure 4. HBP1 is important for keratinocyte differentiation.**

**A.** Confocal Immunofluorescence analysis of human interfollicular skin stained with anti-p63 and anti-HBP1 antibodies. **B.** Quantification of differentiation markers by qRT-PCR of HBP1-inactivated cells induced to differentiate. NHEK were transfected with scramble and HBP1 siRNAs. After 24 hours, half of the cells were induced to differentiate by addition of calcium. Samples were harvested after 7 days, RNA prepared and qPCR performed on the indicated genes. Values are normalized to GAPDH, used as an internal control.

**Figure 5. HBP1 is important for skin stratification.**

H&E staining of skin 3D reconstitution assays after 7 days of stratification. Human primary keratinocytes were cultured on filter, transfected with siCTL (Upper left panel) and siHBP1 (Upper right Panel) and then exposed to 3D conditions. Samples were collected from 2 wells for each condition (upper and lower panels in each conditions). Lower Panels: immunofluorescence analyses of HBP1 and Loricrin expression in 3D reconstituted skin transfected with siCtl (Left) and siHBP1 (Right).

**Figure 6. HBP1 directly regulates Wnt genes in NHEK.**

**A.** Expression of genes of the Wnt pathway in NHEK in which HBP1 levels are altered, positively

or negatively. In the left Panels, qRT-PCR of c-Myc, c-Jun, CyclinD1 and Sost-DC1 upon overexpression of HBP1 for 24 and 48 hours. In the right Panels after HBP1 RNAi inactivation at 48 hours post-transfection. **B.** *In vivo* binding of HBP1. Chromatin Immunoprecipitation of NHEK cells with  $\alpha$ -HBP1 and control  $\alpha$ -Flag antibodies. Amplicons in the c-Jun and CyclinD1 promoters are used to evaluate the specific enrichments of HBP1 relative to the control antibody. Right panels show a schematic representation of the c-Jun and CyclinD1 promoter loci, with black and grey dots indicating, respectively, *in silico* HBP1 and p63 sites in the appropriate position. The black bars indicate the amplicons used in the ChIP experiments.

**Figure 7. Validation of gene expression profiling.**




q-RTR-PCR analysis of HBP1 activated and repressed targets that emerged from the expression profiling of HBP1-inactivated NHEK. The values of the indicated mRNAs in NHEK in which HBP1 was inactivated are plotted with those of NHEK transfected with a control Scramble siRNA.

**Figure 8. Gene Ontology categorization of HBP1-regulated genes in NHEK.**



Gene Ontology analysis of HBP1 targets. For the Biological Processes categorization, we considered terms with p values  $< 10^{-6}$ , for Cellular Components and Molecular Function  $< 10^{-5}$ .


**Figure 9. Scheme of expression of HBP1 targets in human skin.**






Borrelli et al., Fig. 1

**A****B**




Borrelli et al., Fig. 3


**A**





**B**




Borrelli et al., Fig. 4



Borrelli et al., Fig. 5




Borrelli et al., Fig. 6



Borrelli et al., Fig. 7

<b>BIOLOGICAL PROCESS</b>	<b>p.val</b>	<b>ANALYZED GENES</b>
negative regulation of epithelial cell proliferation	2.17e-10	KRT4 RARRES1 RARRES3 TGFB2
tissue development	2.17e-06	KRT1 KRT9 TGFB2 SPINK5
regulation of epithelial cell proliferation	7.92e-09	KRT4 TGFB2
epithelial cell proliferation	2.73e-07	KRT4 TGFB2
epidermis development	3.58e-06	KRT1 KRT9 TGFB2 SPINK5
negative regulation of cell proliferation	3.8e-06	KRT4 RARRES1 RARRES3 TGFB2
ectoderm development	6.38e-06	KRT1 KRT9 TGFB2 SPINK5
extracellular structure organization and biogenesis	3.17e-07	TGFB2 SPOCK2 SPINK5
extracellular matrix organization and biogenesis	1.16e-06	TGFB2 SPOCK2 SPINK5
chemotaxis	3.2e-06	PDGFB TGFB2 ROBO3
axon guidance	4.58e-06	SLIT1 SLIT3 TGFB2 ROBO3
hormone metabolic process	6.99e-06	SRD5A1 RDH11 RDH12
behavior	7.18e-06	EGR2 PDGFB TGFB2 ROBO3
cell motility	7.75e-06	PDGFB SLIT1 SLIT3 TGFB2 ROBO3
phosphate transport	8.11e-06	
defense response to bacterium	9.38e-06	
<b>CELLULAR COMPONENT</b>		
extracellular space	2.17e-10	SLIT1 SLIT3 TNFSF10 TNFSF9 LIF
secretory granule	1.52e-07	PDGFB TGFB2 SPINK5
cytoplasmic membrane-bounded vesicle lumen	3.27e-07	PDGFB TGFB2
extracellular matrix	7.02e-07	SPOCK2
intermediate filament cytoskeleton	1.29e-06	KRT1 KRT4 KRT9 KRT81 KRT23 KRT79
basement membrane	3.26e-06	
extracellular matrix part	4.73e-06	
<b>MOLECULAR FUNCTION</b>		
extracellular matrix structural constituent	2.85e-06	
serine-type endopeptidase inhibitor activity	6.99e-06	SPINK5
endopeptidase inhibitor activity	1.53e-05	SPINK5
enzyme inhibitor activity	2.57e-05	SPINK5
endopeptidase activity	7.59e-05	
cytokine activity	8.91e-05	PDGFB TGFB2 TNFSF10 TNFSF9





Borrelli et al., Fig. 9